SynthesisJournal of cancer research and clinical oncology2020

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.

Thierry Landre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.